Le Lézard
Classified in: Health, Science and technology
Subject: Lawsuit

Monsanto Wins Appeal Ruling in Erickson v. Monsanto


Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto's favor on multiple grounds.

This decision reverses the initial verdict of $185 million in its entirety and remands the case back to trial court for further proceedings.

The company stated:

"This is a very significant ruling in favor of Monsanto because the Court of Appeals identified multiple errors - that cut across most Sky Valley Education Center (SVEC) trials that have been completed - including the unreliability of Plaintiffs' exposure evidence that was erroneously admitted in all SVEC cases tried to date. Specifically, the Court of Appeals held that the trial court improperly denied the Company's statute of repose defense, erroneously admitted a major portion of plaintiffs' key expert exposure opinions, and wrongfully allowed punitive damages on plaintiffs' post-sale failure to warn.

"The Company will consider its legal options regarding the application of this ruling to other SVEC verdicts that are in conflict with it, as well as how this ruling could affect future trials."

The SVEC cases represent most of PCB-related personal injury litigation against Monsanto. Erickson is the first personal injury case to go to trial due to alleged PCB exposure at a single school in Washington state.

The evidence in these cases have demonstrated that all measured PCB air concentrations at SVEC fell well below the regulatory health-protective limits and guidelines set by state and federal regulators, and there is no evidence any such exposure to PCBs can and did cause the alleged injuries.


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: